Human Placental Extract and its Formulations is back in India vide the Gazette Notification No. G.S.R 418(E) dated May 30, 2011 - the Ministry of Health & Family Welfare...... USE OF PLACENTREX CONTINUES!
Related Posts Plugin for WordPress, Blogger...

Monday, June 9, 2014

Presentation on Placentrex – an aqueous extract of human placenta at National Conference on 'Complex Diseases, Novel Therapeutics & Delivery Challenges' 2014, India

The presentation on aqueous extract of human placenta at National Conference on 'Complex Diseases, Novel Therapeutics & Delivery Challenges' 2014, India by Dr. Piyali Datta Chakraborty, Scientist, Albert David Ltd, Kolkata opened up before the attendees a lesser known domain for many. Her presentation was based on 'Placentrex' - the commercial flagship product of Albert David Ltd, is a purified extract of human placenta and is commercially available in the Indian market as injections & gel for topical application. The event took place at Gupta College of Technological Sciences (GCTS), Asansol, West Bengal, India during January 23-24, 2014.

Excrept from the proceedings:
*Courtesy: Avik Das*, B.Pharm, M.S (USA) Assistant Professor, Department of Pharmacology, Gupta College of Technological Sciences, Asansol, West Bengal, India *Correspondence:; Tel.:+919748207856
The session of Dr. Piyali Datta Chakraborty, Scientist, Albert David, Kolkata who spoke of the signature product of their company 'Placentrex', which is a purified extract from the placenta of the newborn. Placenta which is the biological life line of the baby in the mother's womb consists of a wide array of biological substances which are known to have immense therapeutic potential. Besides, this biological treasure house also serves as a rich source of pleuripotent stem cells which may help in the repair mechanism of the body. In her talk here, Dr. Chakraborty emphasised specially on the use of the aqueous extract of placenta in the treatment of non healing wounds and also advocated its usage in surgical dressings and burn injuries. She spoke about the different techniques for the commercial production of 'Placentrex' and also discussed shortly about the probable mechanism of action of the product. She also threw light on the benefits of adding proteolytic enzymes in proportionate quantity to the extract to gain a synergistic effect in the process of wound healing. The session indeed opened up before the audience a new idea which in near future is envisaged to become a torchbearer in the field of pharmacotherapeutics i.e. pharmacobiotech.


Sunday, June 8, 2014

USFDA approves Israel-developed stem cell for use in studies

In March 2014, USFDA approved Israeli company Pluristem Therapeutics to mass produce therapeutic human-placenta-derived stem cell products within its commercial-scale manufacturing facility in Haifa, Israel. Pluristem is moving into mass-production of its human placenta-based muscle repair system.
Pluristem’s use of human placenta to boost cell repair involves “a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases.” Though animal placenta, especially from horses, has been a popular form of treatment for cell repair, human placenta offers a naturally compatible genome.

Pluristem’s technology was cleared by the FDA to treat several conditions, The Times of Israel reported, including Buerger’s disease and aplastic anemia – both of which have no other treatment options. The FDA’s move follows the January approval of the process from Germany’s top medical treatment regulator, the Paul Ehrlich Institute.

Read Original Article @
Mass production of placenta stem cells gets FDA approval

Thursday, December 6, 2012

Public perspectives on the utilization of human placentas in scientific research and medicine

Yoshizawa RS.


Centre for Research on Reproductive Health of Campinas (CEMICAMP), University of Campinas, Campinas, Sao Paulo, Brazil. Electronic address:


Placental tissues are frequently utilized by scientists studying pregnancy and reproduction and in diverse fields including immunology, stem cell research, genetics, cancer research, and tissue engineering, as well as by clinicians in many therapies. Though the utilization of the human placenta in science and medicine has benefitted many people, little is known about public perspectives of this phenomenon. This review addresses placental donation, collection, and utilization in science and medicine, focusing on public perspectives. Cultural values and traditions, ethical paradigms and concerns, public understandings of science and medicine, and political considerations may impact perceptions of the utilization of the placenta in science and medicine, but systematic study is lacking. It is argued that knowledge of public views gained from empirical investigation may underpin the development of collection protocols and research projects that are more responsive to public will, spur more extensive utilization in science and medicine of this unique organ, and/or aid in the realization of the mobilization of knowledge about the placenta for clinical and educational ends. New avenues for research on public perspectives of the placenta are proposed.
Copyright © 2012 Elsevier Ltd. All rights reserved.
[PubMed - as supplied by publisher]


Thursday, March 29, 2012

Recent Advances in Research on the Human Placenta

Recently INTECH has published an online book "Recent Advances in Research on the Human Placenta" which provides a comprehensive and updated overview of the human placenta in current scenario. Interested readers can read it online or may download the book (in pdf format) - its free and no registration required.

This book contains the total of 19 chapters, each of which is written by one or several experts in the corresponding field. The objective of this book is to provide a comprehensive and most updated overview of the human placenta, including current advances and future directions in the early detection, recognition, and management of placental abnormalities as well as the most common placental structure and functions, abnormalities, toxicology, infections, and pathologies. It also includes a highly controversial topic, therapeutic applications of the human placenta. A collection of articles presented by active investigators provides a clear update in the area of placental research for medical students, nurse practitioners, practicing clinicians, and biomedical researchers in the fields of obstetrics, pediatrics, family practice, genetics, and others who may be interested in human placentas.

Dr. Jing Zheng
Obstetrics and Gynecology
InTech, March, 2012
Hard cover, 428 pages

The Indian scientists Piyali Datta Chakraborty and Debasish Bhattacharyya have also contributed in this book with their work "Aqueous Extract of Human Placenta as a therapeutic-agent" (Chapter 4).

For Further details, refer to:

Friday, November 11, 2011

USFDA approves first human cord blood product - HEMACORD

U.S. drug regulators have for the first time approved a therapy that uses cells of human blood from the placenta and the umbilical cord to treat people with blood-forming disorders or cancer.

The Food and Drug Administration (USA) on Thursday (Oct 10, 2011) licensed HEMACORD, manufactured by the New York Blood Center (NYBC), a therapy that contains self-recreating cells similar to stem cells from human cord blood. This therapy is known as hematopoietic progenitor cells-cord (HPC-C) cell therapy.

Those blood-forming types of cells, known as progenitor cells, are infused into patients and make their way to bone marrow, where they divide and mature. As they move into the bloodstream, they can help build new blood cells or restore their capacities, including immune function.
Hemacord is approved for use in blood-restoring stem cell transplants, which can use cells from three sources: cords, bone marrow and peripheral blood, the flowing blood that circulates through the body.

"We have been using cord blood for years," said Dr. Machi Scaradavou, medical director of the NYBC's National Cord Blood Program." Recently, FDA decided that it needs to be licensed and this is the first cord blood product and stem cell product to be licensed."
In 2009, the FDA guided manufacturers of such therapies to submit by Oct. 20 applications either for a license or for an approval as an investigational new drug. National Cord Blood Program is the first to get FDA's nod, Scaradavou said.

"The use of cord blood hematopoietic (blood-forming) progenitor cell therapy offers potentially life-saving treatment options," said Dr. Karen Midthun, director of FDA's Center for Biologics Evaluation and Research, in a statement.